logo-loader
viewPreveCeutical Medical Inc

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program.

He says they've now successfully optimised the conditions for extracting cannabinoids from one of their cannabis strains … ''we've also quantified how much of each of those cannabinoids are present within that extract and it falls well within the range of what the provider of that cannabis strain specified to us'', he adds.

''We're very confident now moving forward, developing a standard operating procedure to extract it from the remaining four strains''.

Quick facts: PreveCeutical Medical Inc

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical seeing significant hospital interest for breakthrough...

Stephen Van Deventer, chairman and CEO of PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF) and chief research officer Dr Harry Parekh discuss with Proactive the health sciences specialist's four exciting programmes. Their most advanced is centred around Cannabidiol (CBD) - a...

on 27/2/18

2 min read